Biography
Dr Michael Huo is committed to ensuring his patients receive exceptional, evidence-based cancer care.
Dr Michael Huo is an experienced radiation oncologist, consulting at the following Icon locations: Herston (Gamma Knife), Greenslopes and Redland. Raised in Brisbane, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Queensland (UQ). He completed radiation oncology training in Cairns, Toowoomba and Brisbane, followed by a 12-month clinical fellowship at the world-renowned Princess Margaret Hospital in Toronto, Canada where he subspecialised in Gamma Knife radiosurgery and palliative radiation therapy. In 2019, he became the inaugural Gamma Knife Fellow at the Princess Alexandra Hospital before his appointment as a Staff Specialist in 2020.
He is part of the specialist group of clinicians credentialled to practise at the Icon Herston Gamma Knife facility, reflecting his expertise in advanced intracranial radiation techniques. He also has a public appointment at the PA Hospital and Gamma Knife Centre of Queensland, where he is a Director of Training for Radiation Oncology. In addition to his clinical roles, he is an examiner and senior lecturer for the University of Queensland School of Medicine, a member of the TROG Genitourinary Cancer Working Party, and the Principal Investigator for research studies involving Gamma Knife radiosurgery, kidney SBRT and cardiac radioablation. He has contributed numerous peer-reviewed publications and textbook chapters, in addition to conference presentations at local, national and international levels.
He subspecialises in urological cancers, including prostate, kidney and bladder cancers, as well as Stereotactic Radiosurgery for brain metastases, benign tumours (such as pituitary adenomas and meningiomas), and other intracranial conditions.
Dr Huo is fluent in English and Mandarin, ensuring patients and their families feel comfortable communicating in their preferred language.
Publications
Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. M. Huo, M. Rose, M. van Prooijen, M. Cusimano, N. Laperriere, R. Heaton, F. Gentili, D. Payne, D. Shultz, P. Kongkham, S. Kalia, M. Schwartz, M. Bernstein, J. Spears, G. Zadeh, M. Hodaie & D. Tsang. Neurosurgery, 2022; 90: 140-147.
Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases. J. Gallo, S. Garimall, M. Shanker, J. Castelli, T. Watkins, S. Olson, M. Huo, M.C. Foote & M. Pinkham. Clinical Oncology (R Coll Radiol), 2021.
Renal Cell Carcinoma Metastasis to Meckel’s Cave Treated With Repeat Stereotactic Radiosurgery: A Case Report and Review of the Literature. J. Panizza, M. Pinkham, M. Foote, M. Shanker, K. Horwood & M. Huo. Cureus, 2021; 13.
Stereotactic radiotherapy for large vestibular schwannomas: Volume change following single fraction versus hypofractionated approaches. M. Huo, H. Foley, M. Pinkham, M. Shanker, A. Bernard, M. Jenkins, S. Olson, B. Hall, T. Watkins, C. Jones & M. Foote. Journal of Radiosurgery & SBRT (Stereotactic Body Radiation Therapy), 2020; 7. 11-17.
Efficacy of stereotactic radiosurgery for radiation-induced meningiomas. M. Huo, N. Laperriere, M. van Prooijen, D. Shultz, C. Coolens, M. Hodaie, M. Cusimano, F. Gentili, G. Zadeh, D. Payne, M. Schwartz & D. Tsang. Journal of Neuro-Oncology, 2020. 148(5).